{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"6080","value":"18500"},{"groupId":"OG001","spread":"13100","value":"18200"},{"groupId":"OG002","spread":"12900","value":"23600"},{"groupId":"OG003","spread":"4170","value":"39800"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"2"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"comment":"Standard deviation could not be estimated as insufficient number of participants were available for analysis.","groupId":"OG000","spread":"NA","value":"4670"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"comment":"Standard deviation could not be estimated as insufficient number of participants were available for analysis.","groupId":"OG002","spread":"NA","value":"6730"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Cycle 5 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"2"}],"units":"Participants"}],"description":"Participants were not available for analysis in 15 mcg/kg (Cycles 3 and 5), 6 mcg/kg (Cycle 5), 9 mcg/kg (Cycles 3 and 5), 12 mcg/kg (Cycle 3), hence no PK data was collected and analyzed for these doses and cycles. Here, min\\*ng/mL means minute\\*nanogram per milliliter.","dispersionType":"Standard Deviation","groups":[{"description":"Participants were treated with E7777 6 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part.","id":"OG000","title":"Lead-In Part: E7777 6 mcg/kg"},{"description":"Participants were treated with E7777 9 mcg/kg by IV infusion over 60 minute on 5 consecutive days during every 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-In Part.","id":"OG001","title":"Lead-In Part: E7777 9 mcg/kg"},{"description":"Participants were treated with E7777 12 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part.","id":"OG002","title":"Lead-In Part: E7777 12 mcg/kg"},{"description":"Participants were treated with E7777 15 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part.","id":"OG003","title":"Lead-In Part: E7777 15 mcg/kg"}],"paramType":"MEAN","populationDescription":"Lead-in PK analysis set included all participants who received at least one dose of study drug and from whom at least one valid E7777 PK parameter was obtained. Here \"overall number of participants analyzed\" signifies participants who were evaluable for this outcome measure. Here \"number analyzed\" signifies participants who were evaluable for this outcome measure for given timepoints.","reportingStatus":"POSTED","timeFrame":"Cycles 1, 3, 5 Day 1: Pre-dose up to 300 hours Post-dose (Cycle length was 21 days)","title":"Lead-In Part: Area Under the Curve From Time 0 to Time t (AUC[0-t]) of E7777","type":"SECONDARY","unitOfMeasure":"min*ng/mL"}